 

Active ingredient: Amlodipine Besylate; Olmesartan Medoxomil 

 

Form/Route: Tablets/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-way, crossover in-vivo 

Strength: 10 mg base/ 40 mg 

Subjects: Normal healthy males and females, general population 

Additional Comments: Females should not be pregnant, and if applicable, should practice 
abstention or contraception during the study. 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-way, crossover in-vivo 

Strength: 10 mg base/ 40 mg 

Subjects: Normal healthy males and females, general population 

Additional comments: Please see comment above. 




_____________________________________________________________________________ 

 

Analytes to measure: Amlodipine and olmesartan in plasma 

 

Bioequivalence based on (90% CI): Amlodipine and olmesartan 

 

Waiver request of in-vivo testing: 5 mg base/20 mg, 5 mg base/40 mg and 10 mg base/20 mg 
based on (i) acceptable bioequivalence studies on the 10 mg base/40 mg strength, (ii) acceptable 
dissolution testing across all strengths, and (iii) proportional similarity in the formulations across 
all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 

 


